STOCK TITAN

Applied Dna Scie - APDN STOCK NEWS

Welcome to our dedicated page for Applied Dna Scie news (Ticker: APDN), a resource for investors and traders seeking the latest updates and insights on Applied Dna Scie stock.

Overview

Applied DNA Sciences is a biotechnology company specializing in the enzymatic production and detection of synthetic deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) using advanced polymerase chain reaction (PCR) technologies. The company caters to multiple industries with a focus on nucleic acid-based therapeutics, molecular diagnostics, and forensic authentication to secure supply chains and protect intellectual property.

Core Business Segments

  • Therapeutic DNA Production Services: Leveraging its proprietary Linea DNA platform, the company produces highly pure, scalable synthetic DNA that serves as a critical component in the manufacture of nucleic acid-based therapies, including mRNA therapeutics and DNA vaccines.
  • MDx Testing Services: Through its molecular diagnostics (MDx) capabilities, Applied DNA Sciences performs advanced genetic and clinical laboratory testing. These services are directed at ensuring accurate diagnostic results and personalized treatment strategies, contributing to better patient outcomes.
  • DNA Tagging and Security Products & Services: With innovative solutions like the CertainT platform, the company provides botanical-DNA based security and authentication technology. This system verifies the authenticity of materials in supply chains, thereby protecting brands, assets, and intellectual property from fraud, counterfeiting, and diversion.

Key Technologies and Platforms

Applied DNA Sciences stands out due to its integration of state-of-the-art biochemical processes and robust forensic methodologies. Its proprietary platforms include:

  • Linea DNA: A cell-free, enzymatic production platform that generates high-fidelity synthetic DNA constructs with versatile applications in therapeutics and diagnostics.
  • Linea IVT: This innovative platform pairs DNA IVT templates with a next-generation RNA polymerase, streamlining mRNA production while reducing double-stranded RNA contamination, a critical factor in ensuring product purity and regulatory compliance.
  • CertainT: A comprehensive traceability solution that integrates isotopic testing, DNA tagging, and genomic analyses. This platform delivers multiple key proof points to verify the origin and authenticity of raw materials and finished products, particularly within the textile industry.

Market Position and Strategic Significance

By combining advanced manufacturing protocols with forensic traceability techniques, Applied DNA Sciences provides robust solutions that address critical challenges across various sectors. The company's technologies not only enhance the efficiency of nucleic acid-based therapeutics production but also fortify supply chains against counterfeiting and fraud. Its unique approach of integrating multiple layers of verification underlines its commitment to quality, security, and innovation.

Operational Excellence and Industry Impact

The firm's reliance on enzymatic PCR-based processes sets it apart as an expert in producing synthetic DNA with high scalability and fidelity. This technical proficiency supports a diverse customer base, including pharmaceutical developers, diagnostic laboratories, governmental agencies, and global manufacturers who demand reliable, secure, and innovative solutions. Furthermore, by continuously refining its production and testing methodologies, the company demonstrates a strong dedication to research and development, ensuring its processes remain at the forefront of biotechnology innovation.

Conclusion

Overall, Applied DNA Sciences delivers comprehensive solutions that span from the production of synthetic DNA for advanced therapeutics to the forensic authentication of products in global supply chains. Its balanced focus on clinical, industrial, and security applications positions the company as a multifaceted player in the biotechnology sector, dedicated to enhancing product integrity and operational efficiency through innovative, proof-based technologies.

Rhea-AI Summary
Applied DNA Sciences appoints Beverly Wolgast as executive director of Quality and cGMP Programs
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.55%
Tags
management
-
Rhea-AI Summary
Applied DNA Sciences announces general availability of Linea IVT platform evaluation kits, with compelling economics and potential for commercial-scale contract awards.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.79%
Tags
none
-
Rhea-AI Summary
Applied DNA Sciences files provisional patents for methods to reduce dsRNA byproducts in mRNA therapeutics production.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.41%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.86%
Tags
-
Rhea-AI Summary
Applied DNA Sciences, Inc. will release financial results for Q2 2023 on August 10, 2023. A conference call will be held to discuss the results. Webcast and slide presentation will be available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.29%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.73%
Tags
conferences
-
Rhea-AI Summary
Applied DNA Sciences, Inc. (NASDAQ:APDN) has been invited to present at the Healthcare Virtual Conference Part II on June 20-22, 2023. Dr. James A. Hayward, president and CEO, will participate in a Fireside Chat hosted by Maxim Group. The conference will be live on M-Vest.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.83%
Tags
conferences
-
Rhea-AI Summary
Applied DNA Sciences, Inc. announces financial results for Q2 2023 and highlights progress in the enzymatic production of DNA for biotherapeutic applications. The company has identified an acquisition target to expand its commercial advantages in mRNA production. They are on track to deliver cGMP-quality linearDNA production by the end of 2023. The company is also pursuing opportunities in clinical laboratory services and supply chain traceability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.93%
Tags
Rhea-AI Summary
Applied DNA Sciences, Inc. (NASDAQ: APDN) will release its financial results for the three months ended March 31, 2023 after the market close on May 11, 2023. The company will host a conference call at 4:30 p.m. ET on the same day to discuss the results and answer questions. The conference call will be available for replay for 7 days. An accompanying slide presentation will be embedded in the webcast and can be accessed on the Applied DNA website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3%
Tags
conferences earnings

FAQ

What is the current stock price of Applied Dna Scie (APDN)?

The current stock price of Applied Dna Scie (APDN) is $0.811 as of April 17, 2025.

What is the market cap of Applied Dna Scie (APDN)?

The market cap of Applied Dna Scie (APDN) is approximately 1.0M.

What is the core business of Applied DNA Sciences?

Applied DNA Sciences is focused on the enzymatic production and detection of synthetic DNA and RNA. Its offerings span nucleic acid-based therapeutics, molecular diagnostics, and forensic supply chain security solutions.

How does the company ensure supply chain security?

The company utilizes its proprietary CertainT platform, which combines DNA tagging with isotopic and genomic testing to authenticate materials. This multi-proof approach helps verify origin and protect brands against counterfeiting and diversion.

What are the primary business segments of Applied DNA Sciences?

The company operates across three main segments: therapeutic DNA production services, MDx testing services in molecular diagnostics, and DNA tagging/security products for supply chain authentication.

What technologies support their manufacturing processes?

Applied DNA employs advanced PCR-based enzymatic processes. Its proprietary platforms, such as Linea DNA and Linea IVT, facilitate scalable and high-fidelity production of synthetic DNA and mRNA.

How does the Linea IVT platform enhance mRNA production?

The Linea IVT platform combines DNA IVT templates with a proprietary RNA polymerase, significantly reducing double-stranded RNA contamination and streamlining the mRNA manufacturing workflow.

Who are the typical customers of Applied DNA Sciences?

The company's customers include pharmaceutical and biotechnology firms, diagnostic laboratories, governmental agencies, and industrial manufacturers that require secure, high-quality nucleic acid solutions.

How does Applied DNA Sciences maintain quality and product integrity?

Through rigorous process development and the use of state-of-the-art enzymatic production technologies, the company ensures high fidelity and consistency in its synthetic DNA products, while forensic traceability measures further authenticate its outputs.

In what ways does Applied DNA contribute to innovation in biotechnology?

By integrating advanced PCR technology with forensic authentication and scalable production platforms, the company provides innovative solutions that address both clinical and industrial challenges, fostering greater efficiency and security in genetic medicine and supply chain management.
Applied Dna Scie

Nasdaq:APDN

APDN Rankings

APDN Stock Data

1.01M
888.82k
19.47%
26.9%
5.44%
Diagnostics & Research
Services-testing Laboratories
Link
United States
STONY BROOK